Prevention

A video breakdown of the past week's developments and news in leading vaccine candidates.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

In a move being ill-received by clinicians, the COVID-19 vaccine producer is lessening the count of vials being supplied to the government through July.

Current trial evidence is severely lacking for the at-risk group, but does clinical history suggest safety?

An interview on new survey data suggesting a majority of fertility and pregnant patients are not interested in the currently available vaccines.

State and federal officials confirmed Friday that promise for a reserve supply of vaccines meant for second doses is actually unavailable.

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.

The country's first authorized vaccine will be first available to healthcare workers and long-term care residents.

The VRBPAC committee voted 17-4, with 1 abstention, to support the benefit-risk profile of BNT162b2 for preventing COVID-19 in persons aged 16 years and older.

The first COVID-19 vaccines in the US will be from the unique platform. An expert explains how they work.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

Here is everything you need to know about the second vaccine submitted for an EUA this year.

A look at the logistical questions which remain with the two leading candidates.

The IDSA representative discusses advances made in recent years, and how foundational guidance could be set by the FDA with input from specialists.

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

Here is what you need to know about BNT162b2, possibly the first vaccine regulated for COVID-19 prevention.

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

Vaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.

The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.

New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.